Bayer Aktiengesellschaft (BAYZF)
| Previous close | 61.67 |
| Open | 61.42 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 61.42 - 61.43 |
| 52-week range | 45.99 - 74.34 |
| Volume | |
| Avg. volume | 9,288 |
| Market cap | 60.35B |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.88 |
| Earnings date | N/A |
| Forward dividend & yield | 2.11 (4.15%) |
| Ex-dividend date | 02 May 2022 |
| 1y target est | N/A |
- Zacks
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
- Zacks
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Reuters
Bayer under investor pressure to speed up CEO changeover
A top-10 shareholder in Bayer on Tuesday called on the group's supervisory board to replace chief executive Werner Baumann quickly, adding to investor pressure to restore trust and revive the German drugmaker's sagging share price. Despite recent improvements in the company's agriculture business and drug development prospects, Bayer shares have been weighed down by litigation related to a product it acquired through its 2018 takeover of Monsanto. Shareholders have also cited a lack of market trust in its top management.
